Intervention
Lixisenatide (AVE0010)
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 26 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownEvaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)NCT03798054 · 2019-02-15
COMPLETEDA Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)NCT02803918 · 2017-05-17
COMPLETEDSafety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanNCT02941367 · 2017-02-23
COMPLETEDEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanNCT02749890 · 2016-05-09
COMPLETEDEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMNCT02058147 · 2014-02-01
COMPLETEDEfficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic PatientsNCT01798706 · 2013-06-01
COMPLETEDEfficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsNCT01768559 · 2013-01-01
COMPLETEDAssessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- MetforminNCT01632163 · 2012-10-01
COMPLETEDPharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without MetforminNCT01596504 · 2012-05-01
COMPLETEDEvaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 DiabetesNCT01572649 · 2012-05-01
COMPLETEDComparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on MetforminNCT01517412 · 2012-02-01
COMPLETEDEffects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 DiabetesNCT01175473 · 2010-08-01
COMPLETEDEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by MetforminNCT01169779 · 2010-07-01
COMPLETEDEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)NCT01147250 · 2010-06-01
COMPLETED24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin GlargineNCT00975286 · 2009-10-01
COMPLETED24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsNCT00976937 · 2009-08-01
COMPLETEDLixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2NCT00931372 · 2009-06-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)NCT00905255 · 2009-05-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)NCT00866658 · 2009-03-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of PioglitazoneNCT00763815 · 2008-09-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminNCT00763451 · 2008-09-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal InsulinNCT00715624 · 2008-07-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of SulfonylureaNCT00713830 · 2008-07-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminNCT00707031 · 2008-06-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminNCT00712673 · 2008-06-01
COMPLETEDGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in MonotherapyNCT00688701 · 2008-05-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED26
Phase mix
PHASE320
PHASE13
PHASE22
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.